

# CCDI, Using Data, and AI

*Warren A. Kibbe, Ph.D., FACMI  
NCI Deputy Director for Data Science and Strategy*


*Meeting of the National Council of Research Advocates*

## Agenda

1. Introduction
2. Update on CCDI
3. Using Data
4. AI and Cancer Research
5. Discussion

# About My Role

- NCI's first Deputy Director for Data Science and Strategy
- Started June 30, 2024
- What does this role entail?



- Advise NCI director and other senior leaders on the **utilization, stewardship, and sharing of data**
- Provide **strategic direction to CBIT** and oversee all aspects of data science for NCI
- Lead NCI's **implementation of the NIH Strategic Plan for Data Science**
- Provide strategic counsel for **key NCI data science initiatives**
- Serve as **senior data science liaison** on NIH and other government committees

# My (Recent) Background

2013 - 2017  
Director, Center  
for Biomedical  
Informatics and  
Information  
Technology  
(CBIIT), **NCI**

2016 - 2017  
Acting Deputy  
Director, **NCI**

2017 - 2024  
**Duke University School  
of Medicine**


- Chief, Translational  
Biomedical Informatics
- Vice Chair,  
Department of  
Biostatistics and  
Bioinformatics,  
**Duke Cancer Institute**
- Chief Data Officer

2024 - Present  
Deputy Director,  
Data Science  
and Strategy,  
**NCI**

# About CCDI

# CCDI's Key Goals

- Gather data from every child, adolescent, and young adult with childhood cancer
- Create a national strategy of molecular characterization to inform diagnosis and treatment
- Develop a platform and tools for clinical and research data to improve prevention, treatment, quality of life, and survivorship
- Engaging the entire childhood cancer care and research community



*Flores-Toro JA et al, J Clin Oncol, 2023*  
*Jagu S et al, Pediatr Blood Cancer, 2024*



## CCDI Stats At a Glance

**317**

Cataloged Datasets  
**Childhood Cancer  
Data Catalog** >

**2,990\***

Participants with  
Available Genomic  
and Clinical Data  
**Molecular  
Characterization  
Initiative** >

**58,867**

Potential Pediatric  
Molecular Targets  
**Molecular Targets  
Platform** >

**1,700,440**

Reported Cases  
Under Age 40  
(1995-2020)  
**National Childhood  
Cancer Registry  
Explorer** >


\* Counts for MCI participants in CCDI Hub and total MCI participants consented may differ.

- Entry point for researchers, data scientists, and citizen scientists
- Information and direct links to CCDI platforms, tools and resources
- New discoveries that impact patient lives

# CCDI Molecular Characterization Initiative (MCI)



- National strategy for appropriate clinical and molecular characterization for every child with cancer:
  - Minimum set of molecular diagnostics
  - Standardized molecular profiling on up to 3,000 children annually
  - Enabling discoveries as clinical data are connected with other datasets
  - Building a clinically annotated biobank for future research from remaining tissues



[cancer.gov/CCDI-molecular](https://cancer.gov/CCDI-molecular)




# Pediatric Cancers

Type	Introduced	Number
Newly diagnosed CNS tumors	March 2022	3095
Soft tissue sarcoma	May 2022	930
Rare tumors	September 2022	416
Neuroblastoma high risk	February 2024	174
Ewing sarcoma	2025	-
Relapsed tumors	Planned	-

## Adding research molecular characterization (2025)

# Childhood Cancer Clinical Data Commons (C3DC)

- Enables researchers to search harmonized participant-level data across studies using a standardized set of pediatric cancer CDEs.
- Expanded from 2 to 18 harmonized datasets
- Updated UI with additional pages
  - Study details page now supports open-source data downloads
- Enhanced C3DC data model to include treatment and treatment response clinical nodes
- Improved user-friendly documentation
- V3 released on July 31
- Access harmonized childhood cancer clinical data <https://clinicalcommons.ccdi.cancer.gov/home>




# Use of Data in Cancer Research

# Patient Data Touchpoints

 Data Touchpoint

## Screening, Diagnosis, Treatment – Molecular Characterization Initiative



## Epidemiology / Population Sciences Data – Familial data, environmental, registry, population studies, disease cohorts

# Current sources of data

molecular



genome



pathology



imaging



labs



notes




sensors




Our ability to generate biomedical data continues to grow in terms of variety and volume


# Data across the cancer research continuum



# Data Science Training



AI  
READY



DATA SCIENTISTS  
& CANCER RESEARCHERS




DIVERSE  
WORKFORCE

# AI and Cancer Research



**Recent advances  
have led to  
promising new  
applications of AI to  
cancer research**



# Rise of Artificial Intelligence



Image generated by AI (DALL·E3)

## Key AI milestones throughout history




Pre-digital computers;  
conceptual / **math models** of how people think

Beginnings of **modern AI**; more math models (not yet computing power)

Researchers at Google introduce **BERT models** (Bidirectional Encoder Representations from Transformers)

**Launch of ChatGPT** (and other **large language models**); huge opportunity to embed AI in cancer research

# Principles for thinking about AI



AI  
READY



TRUSTWORTHY  
& ETHICAL



DIVERSE  
WORKFORCE

# Thank You



**NATIONAL  
CANCER  
INSTITUTE**

[cancer.gov](https://cancer.gov)

[cancer.gov/espanol](https://cancer.gov/espanol)